13 January 2026 | San Francisco, CA

The U.S. Most Favored Nation (MFN) Executive Order could upend global drug pricing as we know it. Some manufacturers are now vowing to launch only at U.S. prices, daring the rest of the world to follow.

What happens if the MFN Executive Order sets the framework for pharmaceutical pricing in the U.S.?

• How will payers and governments in other countries react?
• How might trade policy be used to enforce or react to changes in multinational company pricing strategies?
• Will this open access to China to undercut the US in pricing and establish access agreements?
• Could the U.S. actually raise prices in other countries? Or will this policy mean not launching in certain countries?

Join the CRA-moderated breakfast conversation during the J.P. Morgan Conference on the ripple effects, power shifts, and opportunities created if the world’s largest market attempts to rewrite the rules on pharmaceutical pricing.

To learn more and request a registration, click here.